ELYSSAMED

ElyssaMed® is a spin-off of Gustave Roussy and INSERM. This biotech company is developing the first active cancer immunotherapy based on a cocktail of antigenic peptides (epitopes) derived from the ppCT tumor antigen delivered with an already marketed vaccine adjuvant for clinical use in non-small-cell lung cancer and neuroendocrine tumors. This innovative product, once administered to lung cancer patients, will amplify their specific immune response toward tumor cells expressing the ppCT antigen and lead to the destruction of even immune-escaped cancer cell variants... This immunotherapy is based on the discovery by the founding team's members of the tumor antigen ppCT (Preprocalcitonin), a precursor of the hormone calcitonin (CT)... They demonstrated that ppCT, which is expressed or over-expressed in several human lung tumor types, is capable of inducing a specific immune response in most lung cancer patients and constitutes a promising target for cancer immunotherapy.